false
0001083446
0001083446
2026-06-25
2026-06-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): June 25, 2026
ASTRANA HEALTH, INC.
(Exact Name of Registrant as Specified in Charter)
| Delaware |
001-37392 |
95-4472349 |
| (State or Other Jurisdiction |
(Commission |
(I.R.S. Employer |
| of Incorporation) |
File Number) |
Identification No.) |
1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801
(Address of Principal Executive Offices) (Zip Code)
(626) 282-0288
Registrant’s Telephone Number, Including
Area Code
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
| Common
Stock, $0.001 par value per share |
ASTH |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers. |
On June 25, 2026, Glenn Sobotka, the Chief Accounting Officer and principal
accounting officer of Astrana Health, Inc. (the “Company”), and the Company agreed that Mr. Sobotka will retire from his positions
with the Company effective as of August 7, 2026. Mr. Sobotka’s retirement is not the result of any disagreement with the Company
on any matter relating to the Company’s operations, policies, or practices.
John Vong, who has been appointed as Senior Vice President –
Accounting effective July 1, 2026, will succeed Mr. Sobotka as the Company’s principal accounting officer, effective as of August
7, 2026. Mr. Vong, 52, has previously served as the Company’s Group Vice President, Accounting since March 2025. Prior to that,
Mr. Vong served as the Company’s Chief Accounting Officer and principal accounting officer from November 2022 to March 2025 and
as its Vice President of Finance and Accounting from July 2022 to November 2022. Prior to joining the Company, Mr. Vong served as Vice
President of Finance and Accounting at Prospect Medical Systems, Inc. from February 2016 to July 2022. Mr. Vong began his career as a
certified public accountant with RSM. Mr. Vong received a Bachelor of Science degree in Business Administration from the University of
California, Riverside and a Master of Business Administration degree from the University of California, Irvine.
Effective as of July 1, 2026, Mr. Vong’s annual base salary will
increase to $320,000. Mr. Vong’s target bonus opportunity as a percentage of his annual base salary for 2026 pursuant to his employee
agreement remains unchanged.
There is no arrangement or understanding between Mr. Vong or any other
person pursuant to which he was selected as principal accounting officer of the Company, and there are no family relationships between
Mr. Vong and any of the Company’s directors or executive officers. There are no transactions to which the Company is a party and
in which Mr. Vong has a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
ASTRANA HEALTH, INC. |
| |
|
| Date: July 1, 2026 |
By: |
/s/ Brandon K. Sim |
| |
Name: |
Brandon K. Sim |
| |
Title: |
Chief Executive Officer and President |
